Comparative Pharmacology
Head-to-head clinical analysis: ALA CORT versus APHTHASOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA CORT versus APHTHASOL.
ALA-CORT vs APHTHASOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Aphthasol (amlexanox) is an anti-inflammatory agent that inhibits the formation and release of inflammatory mediators such as histamine and leukotrienes from mast cells, neutrophils, and other inflammatory cells. It also inhibits the activation of eosinophils and neutrophils, and reduces cytokine production, thereby suppressing the immune response involved in aphthous ulcer formation.
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
Adults: 5 mg orally three times daily for 5 days.
None Documented
None Documented
Terminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
Terminal elimination half-life is 1.5 to 2.5 hours. This short half-life supports multiple daily dosing for local therapeutic effect with minimal systemic accumulation.
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Renal excretion of unchanged drug and metabolites accounts for approximately 50-60% of the administered dose, with the remainder eliminated via biliary/fecal routes as metabolites and unchanged drug. Biliary excretion constitutes about 20-30%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid